• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:33:30 PM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EPZM alert in real time by email
    SC 13G/A 1 Epizyme_13G_A6.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 6)* Epizyme, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29428V104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 29428V104 13G Page 2 of 9 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Patrick Lee, MD 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,738,913 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,738,913 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,738,913 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.63% 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 29428V104 13G Page 3 of 9 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Anthony Joonkyoo Yun, MD 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,738,913 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,738,913 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,738,913 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.63% 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 29428V104 13G Page 4 of 9 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Palo Alto Investors LP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,738,913 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,738,913 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,738,913 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.63% 12. TYPE OF REPORTING PERSON (see instructions) OO, IA CUSIP No. 29428V104 13G Page 5 of 9 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) PAI LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,738,913 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,738,913 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,738,913 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.63% 12. TYPE OF REPORTING PERSON (see instructions) OO, IA CUSIP No. 29428V104 13G Page 6 of 9 Pages Item 1. (a) Name of Issuer Epizyme, Inc. (b) Address of Issuer's Principal Executive Offices 400 Technology Square, 4th Floor, Cambridge, MA 02139 Item 2. (a) Name of Person Filing Palo Alto Investors LP ("PAI") PAI LLC ("PAI GP") Patrick Lee, MD ("Dr. Lee") Anthony Joonkyoo Yun, MD ("Dr. Yun") (collectively, the "Filers"). (b) The address of the principal place of the Filers is located at: 470 University Avenue, Palo Alto, CA 94301 (c) For citizenship of Filers, see Item 4 of the cover sheet for each Filer. (d) Title of Class of Securities Common Stock (e) CUSIP Number 29428V104 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (as to PAI) (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (as to Dr. Lee and Dr. Yun) (h) [ ]A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); CUSIP No. 29428V104 13G Page 7 of 9 Pages (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(J). Item 4. Ownership. See Items 5-9 and 11 of the cover page for each Filer. Item 5. Ownership of Five Percent or Less of a Class. N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. PAI is a registered investment adviser and investment adviser of investment limited partnerships, and is the investment adviser to other investment funds. PAI GP is the general partner of investment limited partnerships. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. Dr. Lee and Dr. Yun co-manage PAI. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each of them expressly disclaims membership in a group. Each Filer disclaims beneficial ownership of the Stock except to the extent of that Filer's pecuniary interest therein. Item 9. Notice of Dissolution of Group. N/A CUSIP No. 29428V104 13G Page 8 of 9 Pages Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits. Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 16, 2021 PALO ALTO INVESTORS LP By: /s/ Angela Nguyen-Dinh, Chief Compliance Officer PAI LLC By: /s/ Patrick Lee, MD /s/ Patrick Lee, MD /s/ Anthony Joonkyoo Yun, MD CUSIP No. 29428V104 13G Page 9 of 9 Pages EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of any issuer until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. For that purpose, the undersigned hereby constitute and appoint Palo Alto Investors, LP, a California limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases and sales, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present, until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Dated: February 16, 2021 PALO ALTO INVESTORS LP By: /s/ Angela Nguyen-Dinh, Chief Compliance Officer PAI LLC By: /s/ Patrick Lee, MD /s/ Patrick Lee, MD /s/ Anthony Joonkyoo Yun, MD
    Get the next $EPZM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EPZM

    DatePrice TargetRatingAnalyst
    6/28/2022$1.50Outperform → Market Perform
    Cowen
    6/27/2022Outperform → Neutral
    Wedbush
    3/2/2022$15.00 → $10.00Buy
    HC Wainwright & Co.
    8/10/2021$10.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    8/10/2021$36.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EPZM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Epizyme Inc. (Amendment)

      SC 13G/A - Epizyme, Inc. (0001571498) (Subject)

      9/8/22 4:01:05 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Epizyme Inc.

      SC 13D - Epizyme, Inc. (0001571498) (Subject)

      7/7/22 4:57:01 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Epizyme Inc. (Amendment)

      SC 13D/A - Epizyme, Inc. (0001571498) (Subject)

      6/28/22 8:32:54 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Epizyme Inc.

      15-12G - Epizyme, Inc. (0001571498) (Filer)

      8/23/22 5:03:08 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Epizyme Inc.

      EFFECT - Epizyme, Inc. (0001571498) (Filer)

      8/17/22 12:15:13 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Epizyme Inc.

      EFFECT - Epizyme, Inc. (0001571498) (Filer)

      8/17/22 12:15:10 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Giordano Michael F returned 17,054 shares to the company, closing all direct ownership in the company

      4 - Epizyme, Inc. (0001571498) (Issuer)

      8/16/22 7:03:16 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Goldfischer Carl returned 3,403,005 shares to the company, closing all direct ownership in the company

      4 - Epizyme, Inc. (0001571498) (Issuer)

      8/16/22 7:02:25 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Conroy Kevin T returned 62,318 shares to the company, closing all direct ownership in the company

      4 - Epizyme, Inc. (0001571498) (Issuer)

      8/16/22 7:02:02 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Financials

    Live finance-specific insights

    See more
    • Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

      Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini

      6/27/22 1:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

      TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study Assessing Tazemetostat in Combination with R2 in Follicular Lymphoma (FL) Updated Data from the Phase 1b Portion of SYMPHONY-1 to be Presented at ASCO; Additional Updates Anticipated in 2H 2022 from Tazemetostat and EZM0414 (SETD2 inhibitor) Studies Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients again

      5/10/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Epizyme Announces Date of First Quarter 2022 Financial Results

      Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5369344. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call. About Epizyme, Inc.

      5/3/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TAZVERIK issued to EPIZYME INC

      Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

      8/14/24 4:43:30 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TAZVERIK issued to EPIZYME INC

      Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-4) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 11/16/2023. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

      11/17/23 4:37:35 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Leadership Updates

    Live Leadership Updates

    See more
    • Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update

      Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced a clinical update as well as the appointment of Jerald Korn as Chief Operating Officer, reporting to President and Chief Executive Officer, Grant Bogle. "We are excited to welcome Jerald to Epizyme at a pivotal time for the organization," said Mr. Bogle. "Jerald's breadth of experienc

      3/15/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development

      MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board. Kazumi brings experience as both an entrepreneur and an investor within the field of biotechnology. She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi was also a co-founder and CEO of Mitobridg

      12/3/20 3:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

      TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company's Novel, First-in-Class, Oral SETD2 Inhibitor Merger with Ipsen Expected to Close in 3Q 2022 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. "I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product

      8/9/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

      Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement Epizyme stockholders are encouraged to tender their shares to the offer today Regulatory News: Ipsen S.A. ((Euronext: IPN, OTC:IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ:EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Sha

      8/5/22 1:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

      Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini

      6/27/22 1:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Epizyme downgraded by Cowen with a new price target

      Cowen downgraded Epizyme from Outperform to Market Perform and set a new price target of $1.50

      6/28/22 7:22:14 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Epizyme downgraded by Wedbush

      Wedbush downgraded Epizyme from Outperform to Neutral

      6/27/22 9:12:17 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Epizyme with a new price target

      HC Wainwright & Co. reiterated coverage of Epizyme with a rating of Buy and set a new price target of $10.00 from $15.00 previously

      3/2/22 6:34:32 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care